LSTM’s 118th Annual General Meeting (AGM) was held on Friday 24 November. The meeting saw LSTM’s vice-presidents, the Board of Trustees and Members along with staff and invited guests came together to celebrate the achievements of the last 12 months; vote on a number of governance issues; adopt the Annual Report and Financial Statements for the academic and financial year 2016 - 2017 and discuss the next phase in LSTM’s future.
During the meeting LSTM’s Chairman, James Ross OBE, talked about the extraordinary developments of the last 12 months in which LSTM was granted degree awarding powers, completed the construction of the new Accelerator building and passed the £100 million income level. He paid tribute to Director, Professor Janet Hemingway, who recently announced her intention to retire, stating that LSTM’s successes over the last 17 years have also been her personal successes. He described her as a pioneer who had put LSTM on a sound footing, preparing it for the next phase of expansion and growth.
LSTM’s Director, Professor Janet Hemingway CBE, described the last 12 months as another excellent year with LSTM’s true strength lying in the impact on people and health in the tropics and within the UK. Looking forward she made reference to the three goals set out in LSTM’s new Strategic Plan to strengthen the translational impact of LSTM’s activities, expand LSTM’s teaching portfolio and plan for growth. She described LSTM as the glue bringing together NGOs, ministries of health and communities with opportunities for her successor to take that forward.
Members then officially ratified the 2016/17 Annual Report and Financial Statements – both are available here.
Following the formal part of the meeting Dr Lisa Reimer, from LSTM’s Department of Vector Biololgy, gave a presentation to all present entitled: Lymphatic filariasis: defining transmission breakpoints and sustaining elimination.After the presentation members and guests were given a tour of LSTM’s new Liverpool Life Sciences Accelerator building which is a jointly owned building with the Royal Liverpool & Broadgreen University Hospital NHS Trust. The Accelerator houses LSTM’s antimicrobial and resistance portfolios and will officially open early 2018.